Multiple-potency mechanism of T3D-959.
There is no known cure for Alzheimer’s, and every promising treatment candidate has failed to produce results in large scale clinical trials. Startup company T3D Therapeutics believes that this is because there may be several Alzheimer’s pathologies which have not been adequately addressed by recent attempts to develop an effective medicine. The current general consensus is that insulin resistance in brain cells, which causes symptoms such as glucose imbalance, insulin imbalance and beta amyloid plaque buildup, could be the potential trigger for Alzheimer’s.
Most medicines that have been developed and tested as a treatment option only target one of these abnormalities at a time. T3D claim that their drug is designed to treat many of the abnormalities at once, which could increase the chances of successful results. According to the company website, this medicine operates by acting as an insulin sensitizer, down-regulating BACE expression, up-regulating beta-amyloid degrading enzymes, down-regulating tau phosphorylation, suppressing microglial production of alpha-beta-elicited inflammatory mediators, blocking alpha-beta-peptide induced cell death, and increasing acetylcholine production. The start-up also suggests that the medicine may also have therapeutic effects for patients with other central nervous system disorders, such as Parkinson’s, multiple sclerosis, stroke, or spinal cord injury. If this new drug prevails where all others have failed, in a large scale clinical trail, then this could be an extremely important development in the world of medicine. Only time will tell.
Link: T3D product portfolio…
Med-City News Article: Pharma company developing Alzheimer’s pill that targets link between blood sugar and brain health…
